コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intrave
2 gram per day for 2 weeks, and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 we
4 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg
5 was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those re
6 tion were randomly assigned to four groups; all four groups received sofosbuvir (at a dose of 400 mg once daily) plus rib
8 th dexamethasone, diphenhydramine, and cimetidine, patients received paclitaxel at a dose of 250 mg/m2 by 24-hour infusio
10 dy period, survival was significantly worse among rats that received dantrolene at a dose of 10 mg/kg, irrespective of wh
11 e survival rate was significantly higher among rabbits that received raxibacumab at a dose of 40 mg per kilogram (44% [8
12 eive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to
13 ter a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up
14 egnancies who were at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from
15 ubjects were screened; 1142 (72%) were randomly assigned to receive azithromycin, at a dose of 250 mg daily (570 particip
16 omly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously ever
17 newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patient
18 y virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patie
19 -blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 m
20 ous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once
21 platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for
22 ith radiologic progression within the previous 12 months to receive everolimus, at a dose of 10 mg once daily (207 patien
23 At week 16, patients in the placebo group crossed over to receive guselkumab at a dose of 100 mg every 8 weeks.
24 stage III cutaneous melanoma, we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patie
25 divided by the square of the height in meters] of 36.2) to receive lorcaserin at a dose of 10 mg, or placebo, twice dail
26 ents who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body wei
27 io, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weig
28 ssed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weig
29 We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body wei
31 ned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of bod
32 s with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects),
34 ll, 55 adults with biopsy-confirmed NASH were randomized to receive PTX at a dose of 400 mg three times a day (n = 26) or
35 ave cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo.
36 ry Hodgkin's lymphoma that had already been heavily treated received nivolumab (at a dose of 3 mg per kilogram of body we
37 ce of CMV events was significantly lower among patients who received CMX001 at a dose of 100 mg twice weekly than among p
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。